Moscatilin suppresses the inflammation from macrophages and T cells

Area of Science:

• Immunology
• Hepatology
• Pharmacology

Background:

• Autoimmune liver disease (ALD) poses a significant health challenge.
• Current treatments for ALD have limitations.
• Concanavalin A (ConA)-induced liver injury is a relevant preclinical model for ALD.

Purpose of the Study:

• To investigate the therapeutic potential of moscatilin in a ConA-induced ALD mouse model.
• To elucidate the underlying anti-inflammatory mechanisms of moscatilin.
• To assess moscatilin's effect on key inflammatory markers and cellular responses.

Main Methods:

• Construction of ALD mouse models via ConA injection.
• Administration of varying doses of moscatilin.
• Measurement of serum alanine aminotransferase (ALT) levels.
• Analysis of gene expression for Interferon-gamma (Ifng) and Tumor Necrosis Factor-alpha (Tnfa).
• Assessment of interleukin-37 (IL-37) upregulation in hepatic tissues and cell lines (JS-1, RAW264.7, CTLL-2).

Main Results:

• Moscatilin demonstrated a dose-dependent reduction in ALT levels, indicating decreased liver injury.
• Significant downregulation of Ifng and Tnfa was observed in liver tissues.
• Moscatilin induced IL-37 upregulation in hepatic tissues and specifically in hepatic stellate cells (JS-1) in vitro.
• Immune cells showed limited response to moscatilin in terms of cytokine downregulation.

Conclusions:

• Moscatilin exhibits potent anti-inflammatory and hepatoprotective effects in a ConA-induced ALD model.
• The mechanism involves the upregulation of IL-37, particularly in hepatic stellate cells.
• Moscatilin represents a promising candidate for the development of novel therapeutic agents for ALD.